CreativeOne Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

CreativeOne Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,631	Closed	-$202K	–	1148
2025 Q1	$202K	Buy	+1,631	New	+$213K	0.01%	1006
2023 Q2	–	Sell	-1,523	Closed	-$223K	–	864
2023 Q1	$223K	Buy	+1,523	New	+$225K	0.01%	719

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

CreativeOne Wealth's JAZZ Position: Q2 2025 in Review

CreativeOne Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 1,631 shares — an estimated $202K sold.

CreativeOne Wealth first reported a position in JAZZ in Q1 2023 and held it in 2 quarters. The position peaked at $223K in Q1 2023. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

CreativeOne Wealth reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
CreativeOne Wealth sold 1,631 Jazz Pharmaceuticals shares in Q2 2025, an estimated $202K.
CreativeOne Wealth first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 2 quarters.
CreativeOne Wealth's Jazz Pharmaceuticals position peaked at $223K in Q1 2023.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on CreativeOne Wealth's 13F filing for Q2 2025, filed 12 Aug 2025.